Question

In 2015 the biotech entrepreneur Martin Shkreli bought the marketing rights to Daraprim, which is a drug that treats a parasitic infection. He then raised the price from $13.50 to $750 per pill. Is his conduct in violation of U.S. antitrust laws? In a country that prohibits “Excessive pricing,” would this price hike be illegal? Should the government intervene and pass legislation to put a price cap on the drug? What are the benefits and costs of such a policy?

Answer 1